Phase 1/2 study underway assessing Sangamo’s gene therapy for MPS II; shares ahead 6% premarket – Seeking Alpha
|
Phase 1/2 study underway assessing Sangamo's gene therapy for MPS II; shares ahead 6% premarket
Seeking Alpha The first patient has been dosed in a Phase 1/2 clinical trial, CHAMPIONS, evaluating Sangamo Therapeutics' (NASDAQ:SGMO) gene therapy SB-913 for the treatment of mucopolysaccharidosis type II (MPS II), an inherited lysosomal storage disorder in … |
